Top 10 Companies in the Pharma Neutral Borosilicate Glass Tubing Market (2026): Market Leaders Powering Global Packaging

MARKET INSIGHTS

Global Pharma Neutral Borosilicate Glass Tubing market size was valued at USD 614.15 million in 2024. The market is projected to grow from USD 647.85 million in 2025 to USD 940.84 million by 2032, exhibiting a CAGR of 5.30% during the forecast period.

Pharma Neutral Borosilicate Glass Tubing is a specialized material composed primarily of silicon dioxide and boron trioxide, giving it a low coefficient of thermal expansion (typically 3.3 or 5.0). This composition grants it exceptional chemical durability and high resistance to thermal shock, making it inert and non‑reactive with sensitive pharmaceutical formulations. It is the primary raw material used to manufacture essential primary packaging such as vials, ampoules, and cartridges for injectable drugs.

Market growth is driven by the rising global demand for biologics and injectable drugs, which require highly inert and stable packaging. Stringent regulatory standards for pharmaceutical packaging, such as those from the US FDA and European Medicines Agency, mandate the use of high‑quality glass to ensure drug safety and stability. Recent expansions by key players, for instance Schott AG’s significant investment in 2023 to increase its production capacity, further accelerate the market.

Pharma Neutral Borosilicate Glass Tubing Market – View in Detailed Research Report

Top 10 Companies in the Pharma Neutral Borosilicate Glass Tubing Market

10️⃣ 1. Schott

Headquarters: Mainz, Germany
Key Offering: Type I borosilicate glass tubing, vials, ampoules, and cartridges for injectable drugs

Schott has long been the benchmark for glass quality in the pharmaceutical sector, leveraging its heritage in high‑performance glass manufacturing to deliver products that meet the most demanding regulatory requirements. The company’s continuous investment in R&D and its global network of production sites enable it to respond swiftly to changing market needs.

Sustainability & Growth Initiatives: Schott is expanding its low‑energy melting processes and pursuing circular economy initiatives, including the recycling of glass waste from its own operations.

• Investment in energy‑efficient furnaces
• Partnerships with contract manufacturers for joint innovation
• Expansion of capacity in North America and Asia‑Pacific

9️⃣ 2. Corning

Headquarters: Corning, New York, USA
Key Offering: Advanced borosilicate glass tubing and containers for biologics and vaccines

Corning’s global footprint and strong focus on innovation position it as a key supplier for the rapidly expanding biologics market. The company’s Danner process allows precise control over tube dimensions, meeting the exacting standards of pharmaceutical manufacturers.

Sustainability & Growth Initiatives: Corning is reducing its carbon footprint through renewable energy sourcing and improving material efficiency.

• Renewable energy procurement across manufacturing sites
• Development of lightweight glass formulations
• Strategic alliances with leading vaccine developers

8️⃣ 3. Nipro

Headquarters: Tokyo, Japan
Key Offering: High‑purity glass tubing for injectable drugs and diagnostic cartridges

Nipro’s focus on quality assurance and its integrated manufacturing approach ensure consistent compliance with international pharmacopeial standards. The company’s strong presence in Asia‑Pacific supports local pharmaceutical production.

Sustainability & Growth Initiatives: Nipro is investing in water‑saving technologies and waste reduction programs.

• Water‑efficient furnace operations
• Closed‑loop recycling of glass scrap
• Expansion into emerging markets in Southeast Asia

7️⃣ 4. NEG

Headquarters: Tokyo, Japan
Key Offering: Specialty glass tubing for high‑value biologics and gene therapies

NEG’s niche focus on high‑performance glass for sensitive biologics allows it to capture premium market segments. The company’s commitment to continuous improvement drives innovation in surface treatment technologies.

Sustainability & Growth Initiatives: NEG is integrating digital twins to optimize furnace operations and reduce energy consumption.

• Digital process monitoring
• Advanced surface engineering for delamination resistance
• Strategic joint ventures in China and India

6️⃣ 5. Cangzhou Four Star Glass

Headquarters: Cangzhou, China
Key Offering: Cost‑effective brown and amber borosilicate glass tubing for injectable drugs

The company’s vertically integrated supply chain and aggressive pricing strategy have enabled it to capture significant market share in China’s fast‑growing pharmaceutical sector.

Sustainability & Growth Initiatives: Cangzhou Four Star Glass is upgrading its furnaces to meet stricter emission standards.

• Emission‑controlled melting furnaces
• Local sourcing of silica sand to reduce logistics costs
• Expansion of production capacity to meet vaccine demand

5️⃣ 6. Neubor Glass

Headquarters: Qingdao, China
Key Offering: High‑purity borosilicate glass tubing for injectables and diagnostics

Neubor Glass focuses on quality and speed, providing rapid turnaround for contract manufacturers in the region.

Sustainability & Growth Initiatives: The company is implementing waste‑heat recovery systems in its furnaces.

• Waste‑heat recovery installations
• Rapid production line for prefillable syringes
• Partnerships with regional pharma OEMs

4️⃣ 7. Triumph JunHeng Pharmaceutical Glass

Headquarters: Jinhua, China
Key Offering: Brown and amber glass tubing for injection bottles and ampoules

Triumph JunHeng’s focus on product differentiation and strict quality control has positioned it as a preferred supplier for high‑value biologics.

Sustainability & Growth Initiatives: The company is adopting green manufacturing practices and reducing packaging waste.

• Green manufacturing certification
• Eco‑friendly packaging solutions
• Expansion into Southeast Asian markets

3️⃣ 8. Chongqing Zhengchuan Pharmaceutical

Headquarters: Chongqing, China
Key Offering: Glass tubing for injection devices and ampoules

Chongqing Zhengchuan’s emphasis on speed and reliability makes it a key partner for contract manufacturers handling large volumes of generic injectables.

Sustainability & Growth Initiatives: The company is investing in energy‑efficient glass drawing equipment.

• Energy‑efficient drawing machines
• Rapid scale‑up capabilities
• Collaboration with local pharma clusters

2️⃣ 9. Zhuzhou Kibing Group

Headquarters: Zhuzhou, China
Key Offering: Specialty glass tubing for high‑value biologics and diagnostic cartridges

Zhuzhou Kibing Group leverages advanced glass formulations to meet the stringent requirements of biologics and gene‑therapy products.

Sustainability & Growth Initiatives: The company is focusing on waste reduction and resource optimisation.

• Waste reduction programmes
• Resource optimisation in furnace operations
• Strategic alliances with biotech firms

1️⃣ 10. TUNGHSU GROUP

Headquarters: Shanghai, China
Key Offering: High‑quality brown and amber borosilicate glass tubing for injectable drugs

TUNGHSU GROUP’s strong R&D capabilities and focus on quality compliance have secured it a prominent position in the Asian market.

Sustainability & Growth Initiatives: The company is investing in carbon‑neutral production technologies.

• Carbon‑neutral furnace projects
• Partnerships with global pharma OEMs
• Expansion of capacity in North America

Pharma Neutral Borosilicate Glass Tubing Market – View in Detailed Research Report

Download FREE Sample Report

Download Sample Report

Get Full Report

Pharma Neutral Borosilicate Glass Tubing Market – View in Detailed Research Report

Outlook

Over the next decade, the market will continue to benefit from the expansion of biologics, biosimilars, and advanced therapeutics that demand inert, high‑quality packaging. The regulatory environment remains a stable driver, as agencies worldwide enforce stringent standards for primary containers. The industry’s focus on sustainability, coupled with technological advances in furnace efficiency and surface treatment, will help maintain profitability while meeting environmental expectations.

Future Trends

• Development of delamination‑resistant glass formulations to support cell and gene therapy products.
• Adoption of low‑energy melting processes and renewable energy sources to reduce carbon footprints.
• Growth of prefillable syringe formats and self‑administration devices, increasing demand for precise glass drawing capabilities.
• Expansion of production capacity in emerging markets, particularly in Southeast Asia and India, to support local vaccine and generic drug manufacturing.
• Integration of digital twins and predictive maintenance to optimise furnace operations and reduce downtime.